Hasegawa T, Isobe K, Nakashima I, Shimokata K
First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Biochem Biophys Res Commun. 1993 Aug 31;195(1):409-14. doi: 10.1006/bbrc.1993.2058.
To examine the expression of topoisomerase I and topoisomerase II in primary lung cancer specimens at mRNA level, we carried out Northern blot analysis. As for topoisomerase I expression, there was no remarkable difference between lung cancer specimens and non-cancerous lung tissues. On the other hand, we could detect topoisomerase II mRNA in almost all lung cancer specimens, but not in non-cancerous tissues. By Southern blot analysis, we could not detect large deletion nor rearrangement in DNA level. These results suggest that the expression of topoisomerase II is highly increased in lung cancer at mRNA level and drugs against topoisomerase II might be more tumor-specific than those against topoisomerase I.
为了在mRNA水平检测原发性肺癌标本中拓扑异构酶I和拓扑异构酶II的表达,我们进行了Northern印迹分析。至于拓扑异构酶I的表达,肺癌标本与非癌性肺组织之间没有显著差异。另一方面,我们在几乎所有肺癌标本中都能检测到拓扑异构酶II mRNA,但在非癌性组织中未检测到。通过Southern印迹分析,我们在DNA水平未检测到大片段缺失或重排。这些结果表明,拓扑异构酶II在肺癌中的mRNA水平表达显著增加,针对拓扑异构酶II的药物可能比针对拓扑异构酶I的药物具有更高的肿瘤特异性。